Biogen Inc. BIIB
Regular-session close
Pre-market · Nov 18, 9:02 AM ET
- YTD
- +42.50%
- 1 year
- +52.29%
- Market cap
- 37.07B
- Revenue (ttm)
- 10.30B
- Profit margin
- 3.38%
- EPS (ttm)
- 2.31
- Shares out
- 147.82M
- P/E ratio
- 108.57
- Forward P/E
- 15.43
- YTD return
- +42.50%
- 1-year return
- +52.29%
- 50-day average
- 233.96
- Volume
- 968.96K
- Avg volume
- 1.08M
- Open
- 248.97
- Previous close
- 250.79
- Day's range
- 248.27 – 252.72
- 52-week range
- 160.36 – 261.00
- Beta
- 0.09
- Analysts
- Buy
- Price target
- 268.26 (+7.0%)
- Earnings date
- Feb 5, 2027
5D +1.07 (+0.43%)
Key statistics
- 200-day average
- 205.51
- Enterprise value
- 43.70B
- PEG ratio
- 3.45
- Price / sales
- 3.60
- Price / book
- 1.96
- Revenue growth
- 10.60%
- Free cash flow
- 808.12M
- Total cash
- 1.30B
- Total debt
- 7.80B
- Return on equity
- 1.87%
- Short % of float
- 4.11%
Fundamental scorecard
11 of 25 checks passed on BIIB’s reported financials
11of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 175.00
- Target (mean)
- 268.26
- Target (high)
- 350.00
- Strong buy4
- Buy21
- Hold10
- Sell1
- Strong sell0
Next earnings
Feb 5, 2027
Expected Feb 5, 2027. Consensus EPS estimate 2.81.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 5, 2027 | Dec 30, 2026 | 2.79 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 1.99 | 2.62 | +0.63 | +31.66% |
| Jul 29, 2026 | Jun 30, 2026 | 2.94 | 3.60 | +0.66 | +22.45% |
| Apr 29, 2026 | Mar 31, 2026 | 3.05 | 3.57 | +0.52 | +17.05% |
| Feb 6, 2026 | Dec 31, 2025 | 1.63 | 1.99 | +0.36 | +22.09% |
| Oct 30, 2025 | Sep 30, 2025 | 3.88 | 4.81 | +0.93 | +23.97% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Nov 2, 2026 | Guggenheim | main | Buy | Buy |
| Nov 2, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 29, 2026 | Argus Research | up | Hold | Buy |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- biogen.com
News
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Biogen: 3 Key Takeaways for Long-Term Investors
Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of publicly-traded Biogen Inc. common stock– BIIB Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
Your note
Sign in to keep a note on BIIB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDER SUSAN H | Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 61,889 |
| DORSA CAROLINE D | Director | Stock Award(Grant) | Jun 16, 2025 | 31,002 |
| GREGORY GINGER | Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 22,358 |
| KRAMER ROBIN C. | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 11,471 |
| MANTAS JESUS B | Director | Stock Award(Grant) | Jun 8, 2026 | 11,263 |
| MCDONNELL MICHAEL R | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 9, 2025 | 24,341 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.35% | 16,780,911 | 4.21B | Sep 29, 2026 |
| Blackrock Inc. | 10.88% | 16,089,189 | 4.04B | Sep 29, 2026 |
| Primecap Management Company | 10.28% | 15,197,022 | 3.81B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 9,670,881 | 2.43B | Sep 29, 2026 |
| State Street Corporation | 5.12% | 7,562,205 | 1.90B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.45% | 6,572,163 | 1.65B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 5.66% | 8,359,880 | 2.10B | Jun 29, 2026 |
| Fidelity Contrafund | 3.54% | 5,227,192 | 1.31B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 4,687,985 | 1.18B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 3,827,862 | 959.99M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.16% | 3,199,078 | 802.30M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.86% | 2,745,486 | 688.54M | Jul 30, 2026 |
